Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-nwzlb Total loading time: 0 Render date: 2024-03-29T11:08:51.667Z Has data issue: false hasContentIssue false

5 - Accurately assessing risk in your myeloproliferative neoplasm patient

Published online by Cambridge University Press:  05 March 2016

Ruben A. Mesa
Affiliation:
Mayo Clinic Cancer Center, Arizona
Claire N. Harrison
Affiliation:
Guy’s and St Thomas’ Hospital, London
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Managing Myeloproliferative Neoplasms
A Case-Based Approach
, pp. 37 - 44
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cervantes, F, Passamonti, F, Barosi, G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008; 22:905–14.CrossRefGoogle ScholarPubMed
Beer, PA, Erber, WN, Campbell, PJ, et al. How I treat essential thrombocythemia. Blood 2011; 117:1472–82.CrossRefGoogle Scholar
Cervantes, F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011; 215–21.CrossRefGoogle ScholarPubMed
Michiels, JJ. Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. Clin Appl Thromb Hemost 1999; 5:147–51.CrossRefGoogle ScholarPubMed
Hernández-Boluda, JC, Pereira, A, Cervantes, F, et al. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 2012; 119:5221–8.CrossRefGoogle ScholarPubMed
Rumi, E, Pietra, D, Ferretti, V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 23:1544–51.Google Scholar
Passamonti, F, Thiele, J, Girodon, F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120:1197–201.CrossRefGoogle Scholar
Barbui, T, Finazzi, G, Carobbio, A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization – essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120:5128–33.CrossRefGoogle ScholarPubMed
Passamonti, F. How I treat polycythemia vera. Blood 2012; 120:275–84.CrossRefGoogle Scholar
Kiladjian, J-J, Chevret, S, Dosquet, C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29:3907–13.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):2233.CrossRefGoogle ScholarPubMed
Tefferi, A, Rumi, E, Finazzi, G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27:1874–81.CrossRefGoogle ScholarPubMed
Alvarez-Larrán, A, Pereira, A, Cervantes, F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012; 119:1363–9.CrossRefGoogle ScholarPubMed
Cervantes, F, Dupriez, B, Passamonti, F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012; 30:2981–7.CrossRefGoogle ScholarPubMed
Cervantes, F, Dupriez, B, Pereira, A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895–901.CrossRefGoogle Scholar
Cervantes, F, Pereira, A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep 2012;7:43–9.CrossRefGoogle ScholarPubMed
Guglielmelli, P, Lasho, TL, Rotunno, G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28(9):1804–10.CrossRefGoogle Scholar
Tefferi, A, Guglielmelli, P, Lasho, TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494–500.CrossRefGoogle Scholar
Passamonti, F, Cervantes, F, Vannucchi, AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703–8.CrossRefGoogle Scholar
Gangat, N, Caramazza, D, Vaidya, R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392–7.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×